News & Press review

Here you can find the latest news about Italfarmaco and the international press reviews.

  • 2020 - June 25

    EPICO: EPIgenetic Therapy for the treatment of Coronavirus

    As part of the measures to support the development of collaborations for the identification of therapies and diagnostic, protection and analysis systems to combat the Coronavirus emergency and other viral emergencies of the future, the Lombardy Region has financed the project "EPIgenetic Therapy for the treatment of COronavirus infections "- Acronym: EPICO

  • 2019 - November 13

    Identification of new and highly selective inhibitors of histone deacetylase 6

    The “Journal of Medicinal Chemistry” publishes a paper on the identification of new and highly selective inhibitors of histone deacetylase 6 (HDAC6) by the Italfarmaco drug discovery team.

  • 2019 - March 29

    Italfarmaco Group is pleased to announce the marketing of GhemaXan, the first biosimilar of Enoxaparin Sodium developed and produced in Italy

  • 2019 - February 20

    Gordon Research Conference on Cancer Genetics and Epigenetics

Press review

2024 – March 21

Business Wire

Italfarmaco receives FDA approval for givinostat in Duchenne muscular dystrophy (DMD)

Read the article

2024 – March 19

Business Wire

Italfarmaco Publishes in The Lancet Neurology results from Phase 3 EPIDYS Study in Duchenne Muscular Dystrophy (DMD)

Read the article

2023 – September 05

Business Wire

Italfarmaco Group Receives EMA Validation of Marketing Authorization Application for Givinostat in Duchenne Muscular Dystrophy

Read the article

2023 – June 29

Business Wire

Italfarmaco Group Completes FDA Submission of New Drug Application for Givinostat in Duchenne Muscular Dystrophy and Receives Priority Review

Read the article

2022 – June 25

Business Wire

Italfarmaco Group Announces Positive Topline Data from Phase 3 Trial Showing Beneficial Effect of Givinostat in Patients with Duchenne Muscular Dystrophy

Read the article